The short answer
5-HTP may create a serotonin-related concern with butorphanol, but a direct combination study or well-documented case was not established. Review co-use with the prescriber instead of assuming either proven toxicity or safety.
What this answer covers
Oral L-5-hydroxytryptophan supplements; not ordinary dietary protein.
- Supplement or preparation
- L-5-HTP
- Medication ingredient
- butorphanol
Why the combination raises a question
5-HTP is a serotonin precursor. Its official monograph advises review with medicines that affect serotonin, and the butorphanol labels contain a general serotonergic-drug warning.
What is not demonstrated
The available 5-HTP case involves other serotonergic medicines and several confounders, not butorphanol. It does not establish the incidence or severity of this exact pair. This uncertainty is not evidence that co-use is safe.
Consider all medicines together
Other antidepressants, cough medicines and serotonergic supplements may change the assessment. The label warning supports caution but does not establish a safe 5-HTP dose or a necessary automatic butorphanol dose change.
Review co-use and recognize symptoms
Ask the prescriber or pharmacist before combining them. Seek urgent assessment for a cluster of agitation, fever, tremor, muscle rigidity or confusion. Separating doses by a few hours has not been shown to prevent this concern.
Evidence and practical considerations
Side effects & toxicity
Exact-pair serotonin-syndrome claim lacks direct evidence; current general butorphanol warning and 5-HTP monograph support a narrower conditional precaution, not measured or proven pair toxicity.
- Exact scope
- Oral L-5-hydroxytryptophan supplements; not ordinary dietary protein. with Butorphanol1841 IN; human nasal tartrate or IV/IM tartrate, with route-specific label distinctions.
- Medication form and route
- intranasal medication; intravenous medication; intramuscular medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed butorphanol
Mixed opioid agonist-antagonist with sedation and respiratory-depression warnings; general serotonergic-drug and CYP3A4 interaction precautions.
How this applies: Exact butorphanol RxCUI 1841 IN, with stated salt/formulation/route bridge.
Nasal formulation-specific pharmacokinetic warnings; not an oral drug or veterinary preparation.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed butorphanol
Warns about CNS-depressant combinations and serotonin syndrome with serotonergic drugs.
How this applies: Exact butorphanol RxCUI 1841 IN, with stated salt/formulation/route bridge.
No exact supplement-pair event rate; nasal CYP3A wording is not assumed identical for injection.
Source 3: regulatory supplement monograph
webprod.hc-sc.gc.ca · Source check Sep 10, 2026
Population: Adult oral 5-HTP users
Consult before serotonergic co-use; possible drowsiness. Dextromethorphan-containing cough medicine specifically named among serotonergic products.
How this applies: Original source interpreted for butorphanol only within the stated preparation and endpoint limits.
Not a direct butorphanol combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 4: original case report
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: One patient.
Serotonin syndrome, rhabdomyolysis and compartment syndrome reported.
How this applies: Original source interpreted for butorphanol only within the stated preparation and endpoint limits.
Not a direct butorphanol combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact butorphanol article with formulation-specific evidence and uncertainty. | |
| Research summary published |
Article revision: 5935e6071f78ae39
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.